Edition:
India

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

11.42USD
2:29am IST
Change (% chg)

$-0.26 (-2.23%)
Prev Close
$11.68
Open
$11.68
Day's High
$11.97
Day's Low
$11.26
Volume
5,607
Avg. Vol
14,643
52-wk High
$16.59
52-wk Low
$8.80

Chart for

About

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease... (more)

Overall

No Ratios Available.

Financials

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

25 Jan 2018

BRIEF-Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios

* SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA

21 Dec 2017

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress

04 Oct 2017

BRIEF-Summit Therapeutics announces pricing of public offering $12.00 per ADS

* Summit Therapeutics announces pricing of public offering of 1,459,000 American Depositary Shares

14 Sep 2017

BRIEF-Summit Therapeutics announces proposed public offering of $15 mln of American Depositary shares

* Summit Therapeutics announces proposed public offering of $15.0 million of American Depositary shares Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Summit awarded BARDA contract worth up to $62 million

* Summit awarded BARDA contract worth up to $62 million to support the development of ridinilazole for the treatment of C. difficile infection

11 Sep 2017

BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole

* Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI

05 Sep 2017

BRIEF-Summit Therapeutics reports financial results for Q2 ended July 31 2017

* Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress

31 Aug 2017

Earnings vs. Estimates